Authors
Åke Hjalmarson, Sidney Goldstein, Björn Fagerberg, Hans Wedel, Finn Waagstein, John Kjekshus, John Wikstrand, Dia El Allaf, Jirí Vítovec, Jan Aldershvile, Matti Halinen, Rainer Dietz, Karl-Ludwig Neuhaus, András Jánosi, Gudmundur Thorgeirsson, Peter HJM Dunselman, Lars Gullestad, Jerzy Kuch, Johan Herlitz, Peter Rickenbacher, Stephen Ball, Stephen Gottlieb, Prakash Deedwania, MERIT-HF Study Group, MERIT-HF Study Group
Publication date
2000/3/8
Journal
Jama
Volume
283
Issue
10
Pages
1295-1302
Publisher
American Medical Association
Description
ContextResults from recent studies on the effects of β1-blockade in patients with heart failure demonstrated a 34% reduction in total mortality. However, the effect of β1-blockade on the frequency of hospitalizations, symptoms, and quality of life in patients with heart failure has not been fully explored.ObjectiveTo examine the effects of the β1-blocker controlled-release/extended-release metoprolol succinate (metoprolol CR/XL) on mortality, hospitalization, symptoms, and quality of life in patients with heart failure.DesignRandomized, double-blind controlled trial, preceded by a 2-week single-blind placebo run-in period, conducted from February 14, 1997, to October 31, 1998, with a mean follow-up of 1 year.SettingThree hundred thirteen sites in 14 countries.ParticipantsPatients (n = 3991) with chronic heart failure, New York Heart Association (NYHA) functional class II to IV, and ejection fraction of 0.40 or less who …
Total citations
Scholar articles
Å Hjalmarson, S Goldstein, B Fagerberg, H Wedel… - Jama, 2000